AstraZeneca Plc said that it expects to end the year with higher product sales, offsetting the impact of generic competition for its legacy product Crestor. The expected increase would be in the low single digits, but it would be a major turning point for the company which more than others, has taken a hit from the expiry of patents on blockbuster products.
